Twitter
Advertisement

CSIR's Ayurvedic drug a boon for diabetic patients

The medicine has found a place among the top 20 recommended drugs in a survey conducted by the All Indian Origin Chemists and Distributors (AIOCD). It is the only Ayurvedic drug to have found a place among these top 20 drugs.

Latest News
article-main
The medicine has found a place among the top 20 recommended drugs in an AIOCD survey
FacebookTwitterWhatsappLinkedin

In the wake of an increasing acceptance of Ayurvedic medicines among patients, an anti-diabetic Ayurvedic drug, BGR-34, developed by the Council of Scientific and Industrial Research (CSIR) — the research wing of the Science & Technology Ministry — is helping patients to control and treat diabetes.

The medicine has found a place among the top 20 recommended drugs in a survey conducted by the All Indian Origin Chemists and Distributors (AIOCD). It is the only Ayurvedic drug to have found a place among these top 20 drugs.

BGR- 34, a low cost anti-diabetic Ayurvedic drug, stands for Blood Glucose Regulator, and the numeral represents 34 vital derivatives found in six herbs — Daruharidra, Giloy, Vijayar, Gudmar, Majeeth and Methika — which are used to develop the drug. The AIOCD, which represents over six lakh chemists and druggists across the country, had surveyed 6,367 drugs launched in the last two years from the house of top Indian as well as foreign pharmaceutical companies.

"Patients are extremely happy with the results. People are voluntarily opting for the medicine. Those who are taking it have shared great reports. The sugar levels are going down, they just need to maintain their diet," said Dr Vidula Gujjarwar, Medical Superintendent, Chaudhary Brahm Prakash Ayurved Charak Sansthan, a Delhi government run Ayurvedic clinic in Najafgarh.

Touted as the country's first Ayurvedic drug to treat Type-II diabetes, BGR-34 was jointly developed by two research institutes backed by the Council for Scientific and Industrial Research (CSIR) — National Botanical Research Institute (NBRI) & Central Institute of Medicinal & Aromatic Plants (CIMAP).

The drug, with each tablet that costs Rs 5, is said to have brought about a significant reduction in blood sugar levels in diabetic patients during clinical studies.

Find your daily dose of news & explainers in your WhatsApp. Stay updated, Stay informed-  Follow DNA on WhatsApp.
Advertisement

Live tv

Advertisement
Advertisement